NCT01038856View on ClinicalTrials.gov

Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

December 31, 2012

Study Completion Date

February 28, 2014

Conditions
Polycythemia Vera
Interventions
DRUG

Erlotinib

Erlotinib supplied as tablets; oral dose of erlotinib of 150 mg daily to be continued for 16 weeks. Responders will continue for up to 12 months, non-responders will cease taking erlotinib

Trial Locations (1)

73104

University of Oklahoma Health Sciences Center, Oklahoma City

Sponsors

Collaborators (1)

OSI Pharmaceuticals
All Listed Sponsors
collaborator

OSI Pharmaceuticals

INDUSTRY

lead

University of Oklahoma

OTHER